During a live event, Yelena Y. Janjigian, MD, moderated a discussion on how to use PD-L1 CPS status when considering ...

James Essell, MD, Sarah Cannon Research Institute at OHC, the US Oncology Network, discusses the benefits of a remote ...

Remote therapeutic monitoring significantly lowers infection-related hospitalizations in hematological cancer patients, ...

A 6-month complete response predicts improved long-term survival in high-risk large B-cell lymphoma patients treated with axicabtagene ciloleucel. Results presented at the 2025 ASH Annual Meeting & ...

The LimiTEC trial explored teclistamab discontinuation in multiple myeloma, showing comparable outcomes to continuous therapy with a median PFS of 19.9 months. Fixed-duration therapy may reduce ...

XmAb819 demonstrated a manageable safety profile with primarily grade 1 or 2 cytokine release syndrome and no neurotoxicity in ccRCC patients. The trial involved 69 patients, with a 25% objective ...

Patients who have metastatic chromophobe renal cell carcinoma (ChrRCC) that harbors sarcomatoid features (SF) benefited from immunotherapy (IO)-containing regimens vs patients wit ...

James Essell, MD, is a medical oncologist at Sarah Cannon Research Institute at OHC, the US Oncology Network. Remote therapeutic monitoring significantly lowers infection-related hospitalizations in ...

Axatilimab showed a consistent safety profile in cGVHD patients, with no new safety signals and a decrease in TEAEs over time. The AGAVE-201 trial led to FDA approval of axatilimab at 0.3 mg/kg every ...

Zanubrutinib and venetoclax combination shows an 87% 36-month PFS rate in CLL/SLL patients, regardless of del (17p)/TP53 or IGHV status. The SEQUOIA trial demonstrates durable minimal residual disease ...

New trials reveal INCA033989 shows promise for treating CALR exon 9-mutated myelofibrosis, demonstrating efficacy and tolerability in patients.

Nearly one-third of families face catastrophic financial toxicity during pediatric ALL treatment, with significant household material hardship and income loss. Factors increasing HMH risk include ...